|
|
|
ONLINE FEATURES
Book Reviews
BW Video
Columnists
Interactive Gallery
Newsletters
Past Covers
Philanthropy
Podcasts
Special Reports
BLOGS
Auto Beat
Bangalore Tigers
Blogspotting
Brand New Day
Byte of the Apple
Economics Unbound
Eye on Asia
Fine On Media
Green Biz
Hot Property
Investing Insights
Management IQ
NEXT: Innovation
NussbaumOnDesign
Tech Beat
Working Parents
TECHNOLOGY
J.D. Power Ratings
Product Reviews
Tech Stats
Wildstrom: Tech Maven
AUTOS
Home Page
Auto Reviews
Classic Cars
Car Care & Safety
Hybrids
INNOVATION
& DESIGN Home Page Architecture Brand Equity Auto Design Game Room SMALLBIZ Smart Answers Success Stories Today's Tip INVESTING Investing: Europe Annual Reports BW 50 S&P Picks & Pans Stock Screeners Free S&P Stock Report SCOREBOARDS Hot Growth 100 Mutual Funds Info Tech 100 S&P 500 B-SCHOOLS Undergrad Programs MBA Blogs MBA Profiles MBA Rankings Who's Hiring Grads |  |
AUGUST 21, 2006
Repligen May Hit "A Home Run"  Shares of Biotech Repligen (RGEN
) popped 25%, to 3, on July 31 when a federal judge ruled that its lawsuit seeking royalties from ImClone Systems (IMCL
) could proceed. The suit claims that ImClone is using Repligen's patented technology (licensed from Massachusetts Institute of Technology) to enhance production of ImClone's colon-cancer drug Erbitux. Eric Ende of Merrill Lynch (MER
) in a report says ImClone could end up paying 1% to 2% of Erbitux sales, which Repligen estimates at $1 billion. But for Elemer Piros of Rodman & Renshaw, Repligen's allure is in its products already on the market, plus others in clinical trials, such as secretin for schizophrenia, and uridine, in Phase 2 trials, for bipolar depression. Repligen's Protein A, to boost antibodies, and SecreFlo, to diagnose pancreatitis and gastrinoma, a rare cancer, had sales of $12.5 million in the year ended Mar. 31, 2006. Stanley Medical Research, which funds work on schizophrenia and bipolar disorder, is conducting the studies. Piros rates the stock, now at 2.62, "outperform/speculative," with a 12-month target of 5. He sees 2007 sales of $14 million. Soros Fund Management and Vanguard Group are among the big investors. Private investor Ronald Chez of Ronald L. Chez Inc. which owns shares, predicts Repligen "will hit a home run" with its new products.
Note: Unless otherwise noted, neither the sources cited in Inside Wall Street nor their firms hold positions in the stocks under discussion. Similarly, they have no investment banking or other financial relationships with them.  By Gene G. Marcial
BW MALL
SPONSORED LINKS
Get BusinessWeek directly on your desktop with our RSS feeds.
Buy a link now! Add BusinessWeek news to your Web site with our headline feed. Click to buy an e-print or reprint of a BusinessWeek or BusinessWeek Online story or video. To subscribe online to BusinessWeek magazine, please click here. Learn more, go to the BusinessWeekOnline home page  | | |
 Copyright 2006, by The McGraw-Hill Companies Inc. All rights reserved.Terms of Use | Privacy Notice |
Printer-Friendly Version